

**510(k) Summary**

---

**Introduction** According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

---

**Submitter  
name, address,  
contact** Roche Diagnostics  
9115 Hague Road  
Indianapolis, IN 46250  
317-521-3723

Contact Person: Corina Harper

Date Prepared: Jun 6 , 2005

---

**Device Name** Proprietary name: Elecsys® PreciControl Anemia

Common name: PreciControl Anemia

Classification name: The FDA has classified Multi-Analyte Controls, All Kinds (assayed and unassayed) in Class I.

---

**Predicate  
device** The Elecsys® PreciControl Anemia is substantially equivalent to the currently marketed Elecsys® PreciControl MultiAnalyte (K033937).

---

**Device  
Description** The Elecsys® PreciControl Anemia is a lyophilized product consisting of added Ferritin and Aprotinine in human serum matrix. During manufacture, the analytes are spiked into the matrix at the desired concentration levels.

---

**Intended use** Elecsys® PreciControl Anemia is used for quality control of the Elecsys® Ferritin, Folate II, and Vitamin B12 immunoassays on the Elecsys® immunoassay systems.

---

*Continued on next page*

## 510(k) Summary, Continued

### Comparison to predicate device

The Elecsys® PreciControl Anemia is substantially equivalent to the currently marketed Elecsys® PreciControl MultiAnalyte (K033937). The below tables compare Elecsys® PreciControl Anemia with the predicate device, Elecsys® PreciControl MultiAnalyte (K033937).

### Similarities

Characteristic	Elecsys® PreciControl Anemia	Predicate Device Elecsys® PreciControl MultiAnalyte (K033937)
Intended Use	Elecsys® PreciControl Anemia is used for quality control of the Elecsys® Ferritin, Folate II, and Vitamin B12 immunoassays on the Elecsys® immunoassay systems.	Elecsys® PreciControl MultiAnalyte is used for quality control of the Elecsys® C-Peptide and Elecsys Insulin immunoassays on the Elecsys® immunoassay systems.
Levels	Three	Two
Format	Lyophilized	same
Handling	Reconstitute with exactly 2.0 mL of distilled water and allow to stand closed for 30 minutes to reconstitute, and then mix gently.	Reconstitute with exactly 2.0 mL of distilled water and allow to stand closed for 15 minutes to reconstitute, and then mix gently.
Stability	<u>Unopened:</u> <ul style="list-style-type: none"> <li>• Store at 2-8°C until expiration date</li> </ul> <u>Reconstituted:</u> <ul style="list-style-type: none"> <li>• 20 – 25 °C: up to 8 hrs</li> <li>• on the analyzers at 20-25°C: up to 5 hrs</li> <li>• at 2-8°C: 3 days</li> <li>• at -20°C: 1 month (freeze only once)</li> <li>• after thawing: use only once</li> </ul>	<u>Unopened:</u> <ul style="list-style-type: none"> <li>• Store at 2-8°C until expiration date</li> </ul> <u>Reconstituted:</u> <ul style="list-style-type: none"> <li>• on the analyzers at 20-25°C: up to 3 hrs</li> <li>• at -20°C: 1 month (freeze only once)</li> <li>• after thawing: use only once</li> </ul>

*Continued on next page*

## 510(k) Summary, Continued

---

### Differences

Characteristic	Elecsys® PreciControl Anemia	Predicate Device Elecsys® PreciControl MultiAnalyte (K033937)
Matrix	Human serum with added Ferritin (human origin) and Aprotinine (bovine origin)	Equine serum with added C-Peptide and insulin

---

### Performance Characteristics

The Elecsys® PreciControl Anemia was evaluated for value assignment and stability.

---



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Ms. Corina Harper, RAC  
Regulatory Affairs Consultant  
Centralized Diagnostics  
Roche Diagnostics  
9115 Hague Road  
PO Box 50416  
Indianapolis, IN 46250-0416

JUL 5 - 2005

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Re: k051517  
Trade/Device Name: Elecsys® PreciControl Anemia  
Regulation Number: 21 CFR 862.1660  
Regulation Name: Multi-Analyte controls all kinds (assayed and unassayed)  
Regulatory Class: Class I  
Product Code: JJY  
Dated: June 6, 2005  
Received: June 8, 2005

Dear Ms. Harper:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Carol C. Benson". The signature is written in a cursive, flowing style.

Carol C. Benson, M.A.  
Acting Director  
Division of Chemistry and Toxicology  
Office of *In Vitro* Diagnostic Device  
Evaluation and Safety  
Center for Devices and  
Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known):

K051517

Device Name:

Elecsys® PreciControl Anemia

Indications For Use:

Elecsys® PreciControl Anemia is used for quality control of the Elecsys® Ferritin, Folate II, and Vitamin B12 immunoassays on the Elecsys® immunoassay systems.


Prescription Use XXXX  
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

  
(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K051517

Roche Diagnostics  
Confidential